H

Hyundai BioLand Co Ltd
KOSDAQ:052260

Watchlist Manager
Hyundai BioLand Co Ltd
KOSDAQ:052260
Watchlist
Price: 4 335 KRW 0.93% Market Closed
Market Cap: 130.1B KRW

Hyundai BioLand Co Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hyundai BioLand Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
H
Hyundai BioLand Co Ltd
KOSDAQ:052260
Operating Income
â‚©16.7B
CAGR 3-Years
17%
CAGR 5-Years
10%
CAGR 10-Years
1%
AmorePacific Corp
KRX:090430
Operating Income
â‚©335B
CAGR 3-Years
16%
CAGR 5-Years
6%
CAGR 10-Years
-7%
Amorepacific Group
KRX:002790
Operating Income
â‚©363B
CAGR 3-Years
19%
CAGR 5-Years
5%
CAGR 10-Years
-8%
Cosmax Inc
KRX:192820
Operating Income
â‚©195.4B
CAGR 3-Years
31%
CAGR 5-Years
23%
CAGR 10-Years
20%
LG H&H Co Ltd
KRX:051900
Operating Income
â‚©346.7B
CAGR 3-Years
-29%
CAGR 5-Years
-22%
CAGR 10-Years
-5%
Kolmar Korea Co Ltd
KRX:161890
Operating Income
â‚©223.1B
CAGR 3-Years
38%
CAGR 5-Years
19%
CAGR 10-Years
15%
No Stocks Found

Hyundai BioLand Co Ltd
Glance View

Market Cap
130.1B KRW
Industry
Consumer products

HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.

Intrinsic Value
10 489.38 KRW
Undervaluation 59%
Intrinsic Value
Price
H

See Also

What is Hyundai BioLand Co Ltd's Operating Income?
Operating Income
16.7B KRW

Based on the financial report for Jun 30, 2025, Hyundai BioLand Co Ltd's Operating Income amounts to 16.7B KRW.

What is Hyundai BioLand Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
1%

Over the last year, the Operating Income growth was 63%. The average annual Operating Income growth rates for Hyundai BioLand Co Ltd have been 17% over the past three years , 10% over the past five years , and 1% over the past ten years .

Back to Top